Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Iressa (Gefitinib)

New Hope for Lung Cancer Patients with FDA Approval of Gefitinib

Posted on August 2, 2015
Post Views: 1,673

In July Iressa (Gefitinib)15, the U. S. Food and Drug (FDA) Administration approved IRESSA (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations with an exon 19 deletion or exon 21 (L858R) substitution.

The approval is based on the single-arm phase IV IFUM trial in which gefitinib had an overall response rate of 50% in 106 treatments. This overall response rate was measured by the investigators and an independent review panel, the independent review panel report say that a median duration of response of 6.0 months while the investigators report shown higher overall response rate and median duration of response i.e., 70% and 8.3 months respectably.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research said that “This approval of gefitinib provides further support for a highly targeted approach to treating cancer”.

The open-label IPASS trial subset data, which involved 1217 metastatic non-small cell lung cancer (NSCLC) patients out of which 186 EGFR-positive patients enrolled, also support this approval.

In 2003, IRESSA (gefitinib) get accelerated approval for the treatment of patients with advanced NSCLC after progression on platinum doublet chemotherapy and docetaxel.

IRESSA (gefitinib) may cause side effects like liver damage, interstitial lung disease, gastrointestinal perforation severe diarrhea and ocular disorders. Diarrhea and skin reactions are the most common side effect of gefitinib including rash, acne, dry skin and pruritus, or itching.

But this is great news for metastatic lung cancer patients, as lung cancer is a leading cause of death among men and women. Lung cancer is more common in men but the death rate among women increases. NSCLC is a most common type of lung cancer and about 10 percent of mutations in the EGFR are present in NSCLC. We hope that with the approval of this IRESSA (gefitinib) by FDA death rate among metastatic non-small cell lung cancer (NSCLC) patients decreases.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d